• Inicio
  • Formações
  • Formação à Medida
  • News & Trends
  • Sobre nós
  • Contacto

Quality requirements for drug-device combinations

Draft guideline on the quality requirements for drug-device combinations (PDF/302.99 KB)

Draft: consultation open

First published: 03/06/2019
Consultation dates: 03/06/2019 to 31/08/2019
EMA/CHMP/QWP/BWP/259165/2019

Guidance is provided on dossier requirements for drug-device combinations (DDCs) in the context of a regulatory submission (marketing authorisation application and post-authorisation application). The types of DDCs within the scope of this guideline are medical devices that are integral to the medicinal product, co-packaged with the medicinal product or referenced in the medicinal product information and obtained separately.

News & Trends

Procurar

Recentes

  • HTA Regulation – Commission selects first medical devices for joint clinical assessment
  • PHARMACOVIGILANCE UPDATE | FDA E2B(R3) IMPLEMENTATION GUIDE — OCTOBER 2026
  • updated PIC/S PI 006-4 guideline RECOMMENDATIONS ON QUALIFICATION AND VALIDATION
  • Annual report of the Pharmacovigilance Inspectors Working Group for 2025
  • European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
  • ACT EU workplan 2026 – 2027
  • Advice on ‘end-of-year’ submission dates for type I variations in 2026
  • EMA UPDATE : COMPLIANCE with EU GMP Annex 22 and Artificial Intelligence Standards

91 257 00 03 (Chamada para a rede móvel nacional)
info@formiventos.com

  • Follow
  • CLIENTES & TESTIMONIALS
  • ASSOCIAÇÕES OFICIAIS
  • CERTIFICAÇÕES E CREDITAÇÕES
  • ADVISORY BOARD
  • Política de Privacidade
  • Contacto